The Li Ka Shing Faculty of Medicine of the University of Hong Kong is a medical school which comprises several schools and departments that provide an array of tertiary programmes in medicine, nursing, pharmacy and chinese medicine.

During the past decade, UNIMED Medical Institute conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 6 clinical trials were completed, i.e. on average, 600% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UNIMED Medical Institute" #1 sponsor was "Puma Biotechnology, Inc." with 5 trials, followed by "Organisation for Oncology and Translational Research" with 4 trials sponsored, "Pfizer" with 2 trials sponsored, "Kyoto Breast Cancer Research Network" with 1 trials sponsored and "OBI Pharma, Inc" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UNIMED Medical Institute" #1 collaborator was "Pfizer" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "UNIMED Medical Institute" are "Breast Cancer" (6 trials), "Advanced Breast Cancer" (3 trials), "Advanced Malignant Solid Tumors" (2 trials), "Breast Neoplasms" (2 trials) and "Hormone Receptor Positive Malignant Neoplasm of Breast" (2 trials). Many other conditions were trialed in "UNIMED Medical Institute" in a lesser frequency.

Most popular intervention types in "UNIMED Medical Institute" are "Drug" (13 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Neratinib" (3 trials), "Capecitabine" (2 trials), "Everolimus" (2 trials), "Bosutinib" (1 trials) and "Cyclophosphamide" (1 trials). Other intervention names were less common.

The vast majority of trials in "UNIMED Medical Institute" are 8 trials for "Female" genders and 5 trials for "All" genders.

Currently, there are NaN active trials in "UNIMED Medical Institute". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in UNIMED Medical Institute, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in UNIMED Medical Institute, 4 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".